Benjamin Hohl, CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 10,000 shares at $29.58 ($296K) on 2026-03-06, disclosed to the SEC on 2026-03-10.
Open-market sale of $296k ELVN by CHIEF FINANCIAL OFFICER. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| ELVN | SELL | 2026-07-21 | $317K | — | Filing → |
| ELVN | SELL | 2026-06-22 | $264K | — | Filing → |
| ELVN | SELL | 2025-10-01 | $66K | — | Filing → |